Emerging roles of urotensin-II in cardiovascular disease

Russell, Fraser D. (2004) Emerging roles of urotensin-II in cardiovascular disease. Pharmacology & Therapeutics, 103 3: 223-243. doi:10.1016/j.pharmthera.2004.07.004

Author Russell, Fraser D.
Title Emerging roles of urotensin-II in cardiovascular disease
Journal name Pharmacology & Therapeutics   Check publisher's open access policy
ISSN 0163-7258
Publication date 2004-01-01
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.pharmthera.2004.07.004
Open Access Status Not Open Access
Volume 103
Issue 3
Start page 223
End page 243
Total pages 21
Editor A. C. Sartorelli
D. R. Sibley
M. J. Curtis
Place of publication New York, U.S.A.
Publisher Elsevier
Language eng
Subject C1
320502 Basic Pharmacology
730106 Cardiovascular system and diseases
Abstract Urotensin-II (UII) is a highly potent endogenous peptide within the cardiovascular system. Through stimulation of Galphaq-coupled UT receptors, UII mediates contraction of vascular smooth muscle and endothelial-dependent vasorelaxation, and positive inotropy in human right atrium and ventricle. A pathogenic role of the UT receptor system is emerging in cardiovascular disease states, with evidence for upregulation of the UT receptor system in patients with congestive heart failure (CHF), pulmonary hypertension, cirrhosis and portal hypertension, and chronic renal failure. In vitro and in vivo studies show that under pathophysiological conditions, UII might contribute to cardiomyocyte hypertrophy, extracellular matrix production, enhanced vasoconstriction, vascular smooth muscle cell hyperplasia, and endothelial cell hyper-permeability. Single nucleotide polymorphisms of the UII gene may also impart a genetic predisposition of patients to diabetes. Therefore, the UT receptor system is a potential therapeutic target in the treatment of cardiac, pulmonary, and renal diseases. UT receptor antagonists are currently being developed to prevent and/or reverse the effects of over-activated UT receptors by the endogenous ligand. This review describes UII peptide and converting enzymes, and UT receptors in the cardiovascular system, focusing on pathophysiological roles of UII in the heart and blood vessels. (C) 2004 Elsevier Inc. All rights reserved,
Keyword Pharmacology & Pharmacy
Pulmonary Hypertension
Congestive Heart Failure
Endothelin-converting Enzyme
Nitric-oxide Synthase
Angiotensin-aldosterone System
Primary Pulmonary-hypertension
Mildly Oxidized Ldl
Q-Index Code C1

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: 2005 Higher Education Research Data Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 51 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 55 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 15 Aug 2007, 13:16:30 EST